ストックスクリーナーアプリを入手
2.40
1.23%
-0.03
アフターアワーズ：
2.41
0.01
+0.42%
前日終値:
$2.43
開ける：
$2.42
24時間の取引高:
1.03M
Relative Volume:
0.79
時価総額：
$432.85M
収益：
$109.16M
当期純損益:
$-107.78M
株価収益率:
-2.1694
EPS:
-1.1063
ネットキャッシュフロー:
$-95.45M
1週間 パフォーマンス:
-0.41%
1か月 パフォーマンス:
+12.68%
6か月 パフォーマンス:
+166.67%
1年 パフォーマンス:
+332.35%
1日の値動き範囲:
$2.31
$2.466
1週間の範囲:
$2.285
$2.55
52週間の値動き範囲:
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
名前
Century Therapeutics Inc
セクター
電話
215-981-4000
住所
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.40 | 441.87M | 109.16M | -107.78M | -95.45M | -1.1063 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | TD Cowen | Buy |
| 2024-08-08 | 開始されました | Rodman & Renshaw | Buy |
| 2023-08-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 開始されました | Chardan Capital Markets | Buy |
| 2022-10-31 | 開始されました | Guggenheim | Buy |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-05-23 | 開始されました | H.C. Wainwright | Buy |
| 2022-05-12 | 開始されました | William Blair | Mkt Perform |
| 2021-07-13 | 開始されました | BofA Securities | Buy |
| 2021-07-13 | 開始されました | JP Morgan | Overweight |
| 2021-07-13 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Century Therapeutics Inc (IPSC) 最新ニュース
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Index - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Value Benchmark - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM:IPSC) added to Russell Microcap Value Benchmark Index - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell Microcap Index - marketscreener.com
Century Therapeutics, Inc. Actuals & Estimates (NASDAQ:IPSC) - TradingView
Enterprise value to EBIT forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Price to earnings forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
IPSC Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Century Therapeutics updates its CAR-T pipeline, shares trade on Nasdaq - AD HOC NEWS
Century Therapeutics Inc (IPSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight - GlobeNewswire Inc.
Century Therapeutics Inc (IPSC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Century Therapeutics Inc (IPSC) Institutional Confidence - TradingKey
Century Therapeutics Inc (IPSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Century Therapeutics Inc (IPSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Century Therapeutics Inc (IPSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Century Therapeutics Inc (IPSC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Century Therapeutics Inc (IPSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Century Therapeutics Inc (IPSC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Century Therapeutics amends chief scientific officer contract to part-time role By Investing.com - Investing.com South Africa
Century Therapeutics amends chief scientific officer contract to part-time role - Investing.com India
Century retains Chad Cowan as part-time Chief Scientific Officer with reduced pay - TradingView
Century Therapeutics (IPSC) shifts Chief Scientific Officer to part-time role with new pay terms - Stock Titan
Century Therapeutics SVP Carr sells $3,691 in company stock By Investing.com - Investing.com India
Century Therapeutics SVP Carr sells $3,691 in company stock - Investing.com
Century Therapeutics executive Gregory Russotti sells $5,767 in stock By Investing.com - Investing.com Nigeria
Century Therapeutics executive Gregory Russotti sells $5,767 in stock - Investing.com
Century Therapeutics (IPSC) executive sells shares to cover RSU tax withholding - Stock Titan
Tax-related share sale by Century Therapeutics (IPSC) SVP Carr - Stock Titan
Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting - Stock Titan
Century Therapeutics (IPSC) CSO reports tax withholding of shares and restated holdings - Stock Titan
Century Therapeutics Shareholders Approve Directors and Share Increase - The Globe and Mail
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation - Yahoo Finance
Century Therapeutics (IPSC) director Alessandro Riva granted 74,000 stock options - Stock Titan
Director Daphne Quimi receives 74,000 stock options at Century Therapeutics (NASDAQ: IPSC) - Stock Titan
Century Therapeutics (IPSC) director receives grant of 74,000 stock options - Stock Titan
Century Therapeutics (IPSC) director granted 74,000 stock options at $2.24 - Stock Titan
Century Therapeutics (IPSC) awards 74,000 stock options to director Kimberly Blackwell - Stock Titan
Century Therapeutics (IPSC) shareholders back higher authorized shares and board slate - Stock Titan
Insider sale notice for IPSC (NASDAQ: IPSC) — 2,584 shares planned; prior disposals listed - Stock Titan
Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813 - Insider Monkey
10 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Century Therapeutics (IPSC) executive logs small automatic share sale for taxes - Stock Titan
Century Therapeutics (IPSC) SVP’s automatic 249-share sale covers RSU tax withholding - Stock Titan
Century Therapeutics (NASDAQ: IPSC) CEO has 463 shares withheld for RSU taxes - Stock Titan
Century Therapeutics, Inc. (IPSC) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow (NASDAQ:IPSC) 2026-06-09 - Seeking Alpha
Century Therapeutics, Inc. (IPSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Century Therapeutics Advances CNTY-813 Diabetes Cell Therapy - TipRanks
Century Therapeutics presents preclinical data on diabetes therapy By Investing.com - Investing.com South Africa
Century Therapeutics Inc (IPSC) 財務データ
収益
当期純利益
現金流量
EPS
Century Therapeutics Inc (IPSC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Carr Douglas | SVP Finance & Operations |
Jun 12 '26 |
Sale |
2.23 |
1,654 |
3,692 |
505,094 |
0.05%
0.74%
大文字化:
|
ボリューム (24 時間):